Phreesia (NYSE:PHR – Get Rating) posted its earnings results on Wednesday. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.10, Zacks reports. Phreesia had a negative return on equity of 50.94% and a negative net margin of 53.89%. The company had revenue of $83.85 million during […]
Shares of Phreesia, Inc. (NYSE:PHR – Get Rating) have earned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price […]
Phreesia (NYSE:PHR – Get Rating) and Alight (NYSE:ALIT – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings. Profitability This table compares Phreesia and Alight’s net margins, return on equity […]
Phreesia (NYSE:PHR – Get Rating) had its price objective lowered by KeyCorp from $45.00 to $40.00 in a research report report published on Thursday, The Fly reports. Several other analysts have also issued reports on PHR. Stephens started coverage on shares of Phreesia in a research report on Tuesday, April 11th. They set an overweight […]
Tamarack Advisers LP lifted its position in shares of Phreesia, Inc. (NYSE:PHR – Get Rating) by 9.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 285,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. […]